Skip to Content

EHA24: How I Treat Relapsed/Refractory Multiple Myeloma in Early Lines

Fredrik Schjesvold, Head of Oslo Myeloma Center, discusses his upcoming talk at EHA 2024 in Madrid about selecting second-line treatments for myeloma after the first relapse. He emphasizes considering overall survival and progression-free survival data, changing the mechanism of action, and the potential future impact of new drug combinations on treatment choices.

Fredrik Schjesvold

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top